Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy

References

• Shelburne SA III, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev.5, 67–79 (2003).
   PubMedGoogle Scholar
• French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS18, 1615–1627 (2004).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis.5, 361–373 (2005).
   PubMed Web of Science ®Google Scholar
• Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis.8, 516–523 (2008).
   PubMed Web of Science ®Google Scholar
• Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect. Dis.6, 350–360 (2006).
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Colebunders R, Meintjes G et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: literature review and proposed clinical case definitions. Lancet Infect. Dis.10, 791–802 (2010).
   PubMed Web of Science ®Google Scholar
• Otiti-Sengeri J, Meenken C, van den Horn GJ, Kempen JH. Ocular immune reconstitution inflammatory syndromes. Curr. Opin. HIV AIDS3, 432–437 (2008).
   PubMed Web of Science ®Google Scholar
• Bower M, Nelson M, Young AM et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J. Clin. Oncol.23, 5224–5228 (2005).
   PubMed Web of Science ®Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol.9, 425–437 (2010).
   PubMed Web of Science ®Google Scholar
• Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr. Opin. HIV AIDS3, 438–445 (2008).
   PubMed Web of Science ®Google Scholar
• Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis.10, 251–261 (2010).
   PubMed Web of Science ®Google Scholar
• Phillips P, Bonner S, Gataric N et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin. Infect. Dis.41, 1483–1497 (2005).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Lipman MC, Easterbrook PJ. Immune reconstitution disease associated with mycobacterial infections. Curr. Opin. HIV AIDS3, 425–431 (2008).
   PubMed Web of Science ®Google Scholar
• Breen RA, Smith CJ, Bettinson H et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax59, 704–707 (2004).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS21, 335–341 (2007).
   PubMed Web of Science ®Google Scholar
• Burman W, Weis S, Vernon A et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int. J. Tuberc. Lung Dis.11, 1282–1289 (2007).
   PubMed Web of Science ®Google Scholar
• Navas E, Martin-Davila P, Moreno L et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch. Intern. Med.162, 97–99 (2002).
   PubMed Web of Science ®Google Scholar
• Blanc F-X, Sok T, Laureillard D et al. Significant enhancement in survival with early (2 weeks) vs late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Program and Abstracts of the XVIII International AIDS Conference. Vienna, Austria (2010) (Abstract THLBB1).
   Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med.362, 697–706 (2010).
   PubMed Web of Science ®Google Scholar
• Shelburne SA III, Darcourt J, White AC Jr et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis.40, 1049–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS19, 1043–1049 (2005).
   PubMed Web of Science ®Google Scholar
• Bicanic T, Meintjes G, Rebe K et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J. Acquir. Immune Defic. Syndr.51, 130–134 (2009).
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Filler SG, Chetchotisakd P et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin. Infect. Dis.49, 931–934 (2009).
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J. Infect.53, 357–363 (2006).
   PubMed Web of Science ®Google Scholar
• Serra FC, Hadad D, Orofino RL et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz. J. Infect. Dis.11, 462–465 (2007).
   PubMedGoogle Scholar
• Breton G, Duval X, Estellat C et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin. Infect. Dis.39, 1709–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir. Ther.10, 417–422 (2005).
   PubMed Web of Science ®Google Scholar
• Manabe YC, Kesavan AK, Lopez-Molina J et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb.)88, 187–196 (2008).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS23, 1875–1880 (2009).
   PubMed Web of Science ®Google Scholar
• Shah M, Variava E, Holmes CB et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J. Acquir. Immune Defic. Syndr.52, 145–151 (2009).
   PubMed Web of Science ®Google Scholar
• Letang E, Almeida JM, Miro JM et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in mozambique: a prospective study. J. Acquir. Immune Defic. Syndr.53, 589–597 (2010).
   PubMed Web of Science ®Google Scholar
• Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch. Ophthalmol.116, 169–175 (1998).
   PubMed Web of Science ®Google Scholar
• Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J. Acquir. Immune Defic. Syndr.46, 456–462 (2007).
   PubMed Web of Science ®Google Scholar
• French MA, Lenzo N, John M et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med.1, 107–115 (2000).
   PubMedGoogle Scholar
• Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin. Infect. Dis.42, 418–427 (2006).
   PubMed Web of Science ®Google Scholar
• Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med.6, 140–143 (2005).
   PubMed Web of Science ®Google Scholar
• Grant PM, Komarow L, Andersen J et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE5, e11416 (2010).
   PubMed Web of Science ®Google Scholar
• Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med.158, 157–161 (1998).
   PubMed Web of Science ®Google Scholar
• Cinque P, Pierotti C, Vigano MG et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J. Neurovirol.7(4), 358–363 (2001).
   PubMed Web of Science ®Google Scholar
• Shao HJ, Crump JA, Ramadhani HO et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res. Hum. Retroviruses25, 1277–1285 (2009).
   PubMed Web of Science ®Google Scholar
• Bourgarit A, Carcelain G, Samri A et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative γδ T cells. J. Immunol.183, 3915–3923 (2009).
   PubMed Web of Science ®Google Scholar
• Simonney N, Dewulf G, Herrmann JL et al. Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (Edinb.)88, 453–461 (2008).
   PubMedGoogle Scholar
• Perrin FM, Breen RA, Lipman MC, Shorten RJ, Gillespie SH, McHugh TD. Is there a relationship between Mycobacterium tuberculosis strain type and TB paradoxical reaction? Thorax60, 706–707 (2005).
   PubMedGoogle Scholar
• Price P, Morahan G, Huang D et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS16, 2043–2047 (2002).
   PubMed Web of Science ®Google Scholar
• Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J. Clin. Virol.22, 279–287 (2001).
   PubMed Web of Science ®Google Scholar
• Conesa-Botella A, Mathieu C, Colebunders R et al. Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome? AIDS Res. Ther.6, 4 (2009).
   PubMedGoogle Scholar
• Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr. Opin. HIV AIDS3, 419–424 (2008).
   PubMed Web of Science ®Google Scholar
• French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS6, 1293–1297 (1992).
   PubMed Web of Science ®Google Scholar
• Bourgarit A, Carcelain G, Martinez V et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS20, F1–F7 (2006).
   PubMed Web of Science ®Google Scholar
• Elliott JH, Vohith K, Saramony S et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J. Infect. Dis200, 1736–1745 (2009).
   PubMed Web of Science ®Google Scholar
• Meintjes G, Wilkinson KA, Rangaka MX et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med178, 1083–1089 (2008).
   PubMed Web of Science ®Google Scholar
• Tan DB, Yong YK, Tan HY et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med.9, 307–316 (2008).
   PubMed Web of Science ®Google Scholar
• Tieu HV, Ananworanich J, Avihingsanon A et al. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res. Hum. Retroviruses25, 1083–1089 (2009).
   PubMedGoogle Scholar
• Ruhwald M, Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS21, 882–884 (2007).
   PubMed Web of Science ®Google Scholar
• Tadokera R, Meintjes G, Skolimowska KH et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. DOI: 10.1183/09031936.00091010 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Lim A, D’Orsogna L, Price P, French MA. Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. AIDS Res. Ther.5, 9 (2008).
   PubMedGoogle Scholar
• Seddiki N, Sasson SC, Santner-Nanan B et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur. J. Immunol.39, 391–403 (2009).
   PubMedGoogle Scholar
• Van den Bergh R, Vanham G, Raes G, De Baetselier P, Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect. Dis.6, 2–3 (2006).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS23, 143–145 (2009).
   PubMed Web of Science ®Google Scholar
• Oliver BG, Elliott JH, Saphonn V, Vun MC, French MA, Price P. Interferon-γ and IL-5 production correlate directly in HIV patients co-infected with Mycobacterium tuberculosis with or without immune restoration disease. AIDS Res. Hum. Retroviruses26(12), 1287–1289 (2010).
   PubMedGoogle Scholar
• Boulware DR, Bonham SC, Meya DB et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis.202, 962–970 (2010).
   PubMed Web of Science ®Google Scholar
• Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin. Microbiol. Rev.22, 651–663 (2009).
   PubMedGoogle Scholar
• Leidner RS, Aboulafia DM. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDs19, 635–644 (2005).
   PubMed Web of Science ®Google Scholar
• Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi’s sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi’s sarcoma. Blood93, 4031–4033 (1999).
   PubMed Web of Science ®Google Scholar
• Martin J, Laker M, Clutter D et al. Kaposi’s sarcoma-associated IRIS in Africa: initial findings from a prospective evaluation. Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada (2009) (Abstract 31).
   Google Scholar
• Schrier RD, Song MK, Smith IL et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina26, 165–169 (2006).
   PubMed Web of Science ®Google Scholar
• Mutimer HP, Akatsuka Y, Manley T et al. Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. J. Infect. Dis186, 701–705 (2002).
   PubMedGoogle Scholar
• Stone SF, Price P, Tay-Kearney ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J. Infect. Dis.185, 1813–1817 (2002).
   PubMedGoogle Scholar
• Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet373, 1352–1363 (2009).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS22, 1897–1908 (2008).
   PubMed Web of Science ®Google Scholar
• Tuboi SH, Schechter M, McGowan CC et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J. Acquir. Immune Defic. Syndr.51, 615–623 (2009).
   PubMed Web of Science ®Google Scholar
• Chasombat S, McConnell MS, Siangphoe U et al. National expansion of antiretroviral treatment in Thailand, 2000–2007: program scale-up and patient outcomes. J. Acquir. Immune Defic. Syndr.50, 506–512 (2009).
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, USA, 1–166 (2011).
   Google Scholar
• Keiser O, Anastos K, Schechter M et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop. Med. Int. Health13, 870–879 (2008).
   PubMed Web of Science ®Google Scholar
• Boulle A, Van CG, Hilderbrand K et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS24, 563–572 (2010).
   PubMed Web of Science ®Google Scholar
• Nglazi M, Lawn SD, Kaplan R et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J. Acquir. Immune Defic. Syndr.56, e1–e8 (2011).
   PubMedGoogle Scholar
• Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir. Ther.12, 841–851 (2007).
   PubMed Web of Science ®Google Scholar
• Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst. Rev. DOI: 10.1002/14651858.CD000171.pub2 (2004) (Epub ahead of print).
   Google Scholar
• Golub JE, Saraceni V, Cavalcante SC et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS21, 1441–1448 (2007).
   PubMed Web of Science ®Google Scholar
• Golub JE, Pronyk P, Mohapi L et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS23, 631–636 (2009).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect. Dis.10, 489–498 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Treatment of Tuberculosis. Guidelines for National Programmes. 3rd Edition. WHO/CDS/TB 2003.313. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Getahun H. Meta-analysis to inform the development of a standardised approach for TB screening in HIV-infected patients. Prsented at: 40th Union World Conference on Lung Health, Cancun, Mexico, 3–7 December 2009 (Symposium 2).
   Google Scholar
• Cain KP, McCarthy KD, Heilig CM et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N. Engl. J. Med.362, 707–716 (2010).
   PubMed Web of Science ®Google Scholar
• Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect. Dis.9, 173–184 (2009).
   PubMed Web of Science ®Google Scholar
• Getahun H, Kittikraisak W, Heilig CM et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med.8(1), e1000391 (2011).
   PubMed Web of Science ®Google Scholar
• Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev.3, CD004773 (2005).
   Google Scholar
• Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin. Infect. Dis.23, 827–830 (1996).
   PubMed Web of Science ®Google Scholar
• Scharfstein JA, Paltiel AD, Freedberg KA. The cost–effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med. Decis. Making17, 373–381 (1997).
   PubMed Web of Science ®Google Scholar
• Yazdanpanah Y, Goldie SJ, Paltiel AD et al. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost–effectiveness analysis. Clin. Infect. Dis.36, 86–96 (2003).
   PubMedGoogle Scholar
• Madec Y, Laureillard D, Pinoges L et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS21, 351–359 (2007).
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Sungkanuparph S, Thongyen S et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. J. Med. Assoc. Thai.89, 795–802 (2006).
   PubMedGoogle Scholar
• Apisarnthanarak A, Mundy LM. The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. J. Acquir. Immune Defic. Syndr.47, 644–645 (2008).
   PubMed Web of Science ®Google Scholar
• Parkes-Ratanshi R, Kamali A, Wakeham K et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults. Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, Canada (2009) (Abstract 32).
   Google Scholar
• Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis.48, 856–862 (2009).
   PubMed Web of Science ®Google Scholar
• Meya DB, Manabe YC, Castelnuovo B et al. Cost–effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count 100 cells/µl who start HIV therapy in resource-limited settings. Clin. Infect. Dis.51, 448–455 (2010).
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison TS. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S. Afr. Med. J.100, 378–382 (2010).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS19, 2141–2148 (2005).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS19, 2050–2052 (2005).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care. Med.177, 680–685 (2008).
   PubMed Web of Science ®Google Scholar
• Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex. Transm. Infect.79, 337–338 (2003).
   PubMedGoogle Scholar
• Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect. Dis.10, 93–102 (2010).
   PubMed Web of Science ®Google Scholar
• Bassett IV, Wang B, Chetty S et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin. Infect. Dis51, 823–829 (2010).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS23, 1717–1725 (2009).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS24, 1323–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr. Opin. Pulm. Med.16, 262–270 (2010).
   PubMed Web of Science ®Google Scholar
• Dheda K, Davids V, Lenders L et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS ONE5, e9848 (2010).
   PubMed Web of Science ®Google Scholar
• Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med.30, 701–716 (2009).
   PubMed Web of Science ®Google Scholar
• Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol.48, 229–237 (2010).
   PubMed Web of Science ®Google Scholar
• Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med.363, 1005–1015 (2010).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wood R. Tuberculosis screening in patients starting antiretroviral therapy: stretching diagnostics to the limits. Clin. Infect. Dis.52, 276–277 (2011).
   PubMedGoogle Scholar
• Liechty CA, Solberg P, Were W et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop. Med. Int. Health12, 929–935 (2007).
   PubMed Web of Science ®Google Scholar
• Karavellas MP, Plummer DJ, Macdonald JC et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis.179, 697–700 (1999).
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am. J. Ophthalmol.129, 634–639 (2000).
   PubMed Web of Science ®Google Scholar
• Heiden D, Ford N, Wilson D et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med.4, e334 (2007).
   PubMed Web of Science ®Google Scholar
• Pathai S, Deshpande A, Gilbert C, Lawn SD. Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional study. BMC Infect. Dis.9, 158 (2009).
   PubMed Web of Science ®Google Scholar
• Meintjes G, Rangaka MX, Maartens G et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin. Infect. Dis.48, 667–676 (2009).
   PubMedGoogle Scholar
• Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS21, 2119–2129 (2007).
   PubMed Web of Science ®Google Scholar
• Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet363, 1764–1767 (2004).
   PubMed Web of Science ®Google Scholar
• Bicanic T, Meintjes G, Wood R et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis.45, 76–80 (2007).
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin. Infect. Dis.50, 1532–1538 (2010).
   PubMed Web of Science ®Google Scholar
• Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in Zimbabweans with AIDS and acute cryptococcal meningitis. Clin. Infect. Dis.51, 984–985 (2010).
   PubMedGoogle Scholar
• Boulware DR. Safety, censoring, and intent-to-treat analysis: dangers to generalizability. Clin. Infect. Dis.51, 985–986 (2010).
   PubMedGoogle Scholar
• Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother.53, 1840–1849 (2009).
   PubMed Web of Science ®Google Scholar
• Gofton TE, Al-Khotani A, O’Farrell B, Ang LC, McLachlan RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry DOI:10.1136/jnnp.2009.190652 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Bassett IV, Wang B, Chetty S et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J. Acquir. Immune Defic. Syndr.51, 135–139 (2009).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr. Opin. Infect. Dis.24(1), 34–42 (2010).
   Google Scholar
• Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE4, e5575 (2009).
   PubMed Web of Science ®Google Scholar
• Torok ME, Yen NTB, Chau TTH et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September (2009) (Abstract H-1224).
   Google Scholar
• Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr. HIV/AIDS Rep.6, 162–171 (2009).
   PubMedGoogle Scholar
• Meintjes G, Wilkinson RJ, Morroni C et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS24, 2381–2390 (2010).
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med.351, 1741–1751 (2004).
   PubMed Web of Science ®Google Scholar
• Funderburg N, Kalinowska M, Eason J et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS ONE5, e13188 (2010).
   PubMed Web of Science ®Google Scholar
• Turner JE, Steinmetz OM, Stahl RA, Panzer U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev. Med. Chem.7, 1089–1096 (2007).
   PubMed Web of Science ®Google Scholar
• Martin-Blondel G, Cuzin L, Delobel P et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS23, 2545–2546 (2009).
   PubMed Web of Science ®Google Scholar
• Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol.10, 482–496 (2010).
   PubMed Web of Science ®Google Scholar
• Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol.6, 358–370 (2006).
   PubMed Web of Science ®Google Scholar
• Sun HY, Singh N. Potential role of statins for the management of immune reconstitution syndrome. Med. Hypotheses76(3), 307–310 (2010).
   PubMedGoogle Scholar
• Elliott AM, Halwiindi B, Bagshawe A et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q. J. Med.85, 855–860 (1992).
   PubMedGoogle Scholar
• Elliott AM, Luzze H, Quigley MA et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J. Infect. Dis.190, 869–878 (2004).
   PubMed Web of Science ®Google Scholar
• Volkow PF, Cornejo P, Zinser JW, Ormsby CE, Reyes-Teran G. Life-threatening exacerbation of Kaposi’s sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS22, 663–665 (2008).
   PubMed Web of Science ®Google Scholar